KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Cash from Financing Activities (2018 - 2025)

Historic Cash from Financing Activities for Vir Biotechnology (VIR) over the last 8 years, with Q3 2025 value amounting to $102000.0.

  • Vir Biotechnology's Cash from Financing Activities rose 22903.23% to $102000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year decrease of 1656.61%. This contributed to the annual value of $4.4 million for FY2024, which is 4133.69% down from last year.
  • Latest data reveals that Vir Biotechnology reported Cash from Financing Activities of $102000.0 as of Q3 2025, which was up 22903.23% from $2.0 million recorded in Q2 2025.
  • In the past 5 years, Vir Biotechnology's Cash from Financing Activities ranged from a high of $87.5 million in Q1 2021 and a low of $31000.0 during Q3 2024
  • In the last 5 years, Vir Biotechnology's Cash from Financing Activities had a median value of $2.0 million in 2025 and averaged $7.9 million.
  • Over the last 5 years, Vir Biotechnology's Cash from Financing Activities had its largest YoY gain of 10284470.59% in 2021, and its largest YoY loss of 9888.1% in 2021.
  • Vir Biotechnology's Cash from Financing Activities (Quarter) stood at $5.7 million in 2021, then plummeted by 64.53% to $2.0 million in 2022, then decreased by 16.46% to $1.7 million in 2023, then fell by 24.82% to $1.3 million in 2024, then tumbled by 91.92% to $102000.0 in 2025.
  • Its last three reported values are $102000.0 in Q3 2025, $2.0 million for Q2 2025, and $598000.0 during Q1 2025.